Prin

Phone App Captures Measures of Functional Impairment in MS

THURSDAY, Aug. 12, 2021 -- For persons with multiple sclerosis (MS), a smartphone device captures reliable and clinically relevant measures of functional impairment, according to a study published online July 14 in the Multiple Sclerosis Journal.

Xavier Montalban, M.D., Ph.D., from the Hospital Universitari Vall d'Hebron in Barcelona, Spain, and colleagues assessed performance characteristics of the Floodlight Proof-of-Concept study app in a 24-week study involving 76 people with MS and 25 healthy controls. Smartphone-based active tests and passive monitoring assessed cognition, upper-extremity function, and gait and balance. Test-retest reliability and correlations with clinical and magnetic resonance imaging outcome measures were examined using intraclass correlation coefficients (ICCs) and age- or sex-adjusted Spearman's rank correlation.

The researchers found that across tests, ICCs were moderate to good in persons with MS. For all tests in the cognitive, upper-extremity function, and gait and balance domains, except for the Static Balance Test, the correlations with domain-specific standard clinical disability measures were significant. There were correlations observed for most tests with the Expanded Disability Status Scale, 29-item Multiple Sclerosis Impact Scale items or subscales, and/or normalized brain volume.

"The higher temporal resolution and multidimensional feature space of functional data collected by this platform hold the potential to capture subtle, potentially disease-related information which are not readily discriminated by clinician-administered assessments," the authors write.

Several authors disclosed financial ties to biopharmaceutical companies, including F. Hoffmann-La Roche, which provided study funding.

Abstract/Full Text

© 2021 HealthDay. All rights reserved.

Posted August 2021

Read this next

Multiple Sclerosis Disease Burden Higher in Black Patients

WEDNESDAY, July 14, 2021 -- Black Americans with multiple sclerosis (MS) experience a higher disease burden than White patients, according to a study published online June 30 in...

High-Efficacy Therapy May Reduce Relapses in Active SPMS

TUESDAY, July 13, 2021 -- High-efficacy disease-modifying therapies may reduce flare-ups in recently active secondary progressive multiple sclerosis (SPMS), but they do not appear...

Certain ICD-10 Codes Often Precede Multiple Sclerosis Diagnosis

FRIDAY, June 25, 2021 -- Certain International Classification of Diseases (ICD), Tenth Revision (ICD-10) codes are recorded more frequently before the initial diagnosis in...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.